Available in Guatemala, Spain, United States, Brazil
A randomized, double-blind, parallel group, placebo-controlled multicenter phase 3 study
to evaluate efficacy, safety and tolerability of two regimens of ianalumab on top of
standard-of-care therapy in patients with systemic lupus erythematosus (SIRIUS-SLE 1)
406Patients around the world
